Sphingolipids are a class of bioactive lipids made up of long-chain sphingoid bases vital for cell life. The main sphingolipids include ceramide, ceramide-1-phosphate, glucosylceramide, sphingomyelin, sphingosine, and sphingosine-1-phosphate. In the past, sphingolipids were thought to be merely structural components of cellular membranes. In recent years, they have been described to be molecules involved in signal transduction at cellular and nuclear level. Thus, sphingolipids are now known to mediate cell proliferation, differentiation, apoptosis, cell migration, stress response, neuronal plasticity, angiogenesis, and cancer. Additionally, they are implicated in immune function and inflammatory diseases.

This special issue aims to provide a picture on recent advances in sphingolipid research from leading scientists throughout the world which offers important information on understanding of sphingolipid involvement in inflammation as well as on the identification of new targets for innovative drug treatments.

We invite authors to contribute original research articles, as well as review articles, that will illustrate new technologies for sphingolipid detection and analysis, demonstrate the role of sphingolipids in the regulation of inflammatory mediators in complex ways to promote or inhibit inflammation, clarify the implication of sphingolipid on inflammation component of bowel, spinal cord, lung, brain, kidney, heart, liver, and uterus and other diseases, and identify sphingolipids as predictive and prognostic biomarkers of inflammation.

Potential topics include but are not limited to the following:

• Recent advances in biochemical and microscopy analysis of sphingolipids
• Identification of new mechanisms of inflammation sphingolipid-mediated
• Involvement of sphingolipids in the regulation of inflammatory mediators
• Role of sphingolipids in different diseases
• Identification of sphingolipids as biomarkers for innovative therapy strategies
• Sphingolipid pathway as new pharmacological target in inflammatory diseases
• Sphigolipid agonists in the clinical trials